Two days following the final treatment, tumor-draining lymph node (TDLN) cells were examined by flow cytometry for the presence of activated, proliferating CD8+ T cells, which were defined as CD8+ cells that express CD25 and high levels of CD44. Here, CD8A is linked to neoplasm.